Published Medical Literature

R-CHOP as Front-Line Therapy for Primary Mediastinal LBCL: A View From Jordan

Identifying Factors to Predict Prognosis in Patients With Follicular Lymphoma

Study Explores the Predictive Use of Tumor-Associated Macrophages in DLBCL

Rare MALT Lymphoma in the Thymus and Lung: Case Report

The Cost of CAR T-Cell Therapy in the Second-Line or Third-Line Setting in DLBCL

Bispecific Antibody Glofitamab Under Study in Relapsed or Refractory DLBCL

Clinical Laboratory Mutation Analysis as Predictive Measure in Aggressive B-Cell Lymphomas

Can Real-World Data Be Used to Determine the Effectiveness of Treatments in DLBCL?

Atezolizumab-Based Regimen Under Study in Follicular Lymphoma

Could Zanubrutinib Be an Alternative to Patients With BTK Inhibitor–Intolerant B-Cell Malignancies?

What Can Be Learned About Primary Gastrointestinal DLBCL From Whole-Exome Sequencing?

Using Epigenetic Markers as Prognostic Predictors in Patients With DLBCL

Weighing the Cost-Effectiveness of Immunotherapy Combinations for Patients With DLBCL

Front-Line Therapies With Liposomal Doxorubicin for Advanced B-Cell Lymphomas

What Do We Know About Leukemic Involvement in High-Grade B-Cell Lymphoma?

Can the Malignancy of B-Cell Lymphoid Aggregates Be Determined Via IGH/IGK Analysis?

Exploring Potential Combination Therapies to Overcome Venetoclax Resistance in Mantle Cell Lymphoma

A Novel Minimally Invasive Risk Assessment Tool for Patients With Large B-Cell Lymphoma

Does BTK Inhibitor Therapy Increase the Risk of HBV Reactivation in Those With Advanced DLBCL?

Conditioning Chemotherapy, Lymphocyte Count Kinetics, and Outcomes in LBCL

High-Risk Extranodal Marginal Zone Lymphoma: Novel Predictive Model Under Study

Polypharmacy and Potentially Inappropriate Medications: Predictors of Frailty in Older Patients With Hematologic Malignancies?

ASTCT Panel Opinion: Use of CD19 CAR T Cells in Large B-Cell Lymphoma

Real-World Study in Mantle Cell Lymphoma: Treatment Patterns and Outcomes

Overcoming Resistance to TP53-Mediated Chemoimmunotherapy in B-Cell Malignancies

Risk of Breakthrough COVID Infection After Vaccination in Patients With Hematologic Malignancies

First-Line Treatment Patterns and Outcomes Offer Considerations for Future Trial Design in Mantle Cell Lymphoma

Are Bone Marrow Biopsies Relevant for Response Assessment in Patients With Follicular Lymphoma?

Use of Tisagenlecleucel at Outpatient Facilities for Patients With Lymphoma

First-Line Radioimmunotherapy for Follicular Lymphoma: Long-Term Follow-up

Triggering Anticancer Immunity in DLBCL With Combination Inhibition of CD47/SIRPα

Does a Tamoxifen-Sensitive Target Exist in Diffuse Large B-Cell Lymphoma?

Is Frailty a Predictor of Survival in Patients With Newly Diagnosed DLBCL?

Chemotherapy-Free GALEN Combination for Advanced Follicular Lymphoma

Dual-Targeted Chimeric Antigen Receptor NK-92 Cells Under Study in B-Cell Malignancies

Identifying the Optimal Doses of Ibrutinib and Venetoclax in Resistant Mantle Cell Lymphoma

Predicting Survival Outcomes With PET Radiomics in Diffuse Large B-Cell Lymphoma

From the Haematological Malignancy Research Network: Expanded Database May Yield Insights in B-Cell Lymphomas

Clinical Characteristics of Diffuse Large B-Cell Lymphoma Manifesting in the Jaw

Does Microenvironment Impact the Pathogenesis of MALT Lymphomas?

Does the MYC/MYB/ZDHHC11 Network Impact the Growth of B-Cell Malignancies?

First-Line Ibrutinib Plus Rituximab in Elderly Patients With Mantle Cell Lymphoma

Loncastuximab Tesirine-lpyl for DLBCL: Quality of Life for Older Versus Younger Patients

Prognostic Analyses of Genetic Subtypes Within Diffuse Large B-Cell Lymphoma

Immunogenicity Profile of Tisagenlecleucel in Diffuse Large B-Cell Lymphoma

Biomarkers and Pathways Associated With B-Cell Lymphoma

Exploring the Function of Transcription Factor 3 and Histone Deacetylase 3 in Burkitt Lymphoma

Impact of FLI1 Expression Levels in Germinal Center–Derived DLBCL

Heterologous SARS–CoV-2 Vaccination for Patients With B-Cell Lymphoma

Zanubrutinib Monotherapy for Mantle Cell Lymphoma: Pooled Analysis of Two Trials

Phase II Trial of Combination Therapy for Children and Adolescents With Primary Mediastinal B-Cell Lymphoma

Polatuzumab Vedotin-piiq–Based Salvage Chemotherapy for DLBCL

The Role of Protein Kinase CK1α in Mantle Cell Lymphoma

Zanubrutinib Versus Standard BTK Inhibitors in B-Cell Malignancy: Pooled Safety Analysis

Early-Phase Study of Combination BTK and PI3K Inhibition as B-Cell Lymphoma Therapy

Polatuzumab Vedotin-piiq–Based Therapy for Previously Untreated DLBCL: POLARIX Trial

Older Patients With Mantle Cell Lymphoma: Phase II Trial Focuses on Ibrutinib Plus Rituximab

Tisagenlecleucel Versus Standard of Care in Second-Line Therapy for Aggressive B-Cell Lymphomas

Evaluation of B-Cell Gene Signatures Using Immunomagnetic Cell Separation

Predictability of MCL1 and BCL2 Expression as Sensitivity Biomarkers in B-Cell Lymphomas

Axicabtagene Ciloleucel Versus Standard-of-Care Therapy for Resistant B-Cell Lymphoma

Prognostic Factors of Rheumatic Disease–Associated DLBCL